Relevance of biomarkers across different neurodegenerative diseases
Background The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer’s disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field. Purpose of review Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer’s Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Alzheimer's research & therapy - 12(2020), 1 vom: 13. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ehrenberg, Alexander J. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Alzheimer’s disease |
|---|
| doi: |
10.1186/s13195-020-00601-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR039698858 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR039698858 | ||
| 003 | DE-627 | ||
| 005 | 20230519230011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-020-00601-w |2 doi | |
| 035 | |a (DE-627)SPR039698858 | ||
| 035 | |a (SPR)s13195-020-00601-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Ehrenberg, Alexander J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relevance of biomarkers across different neurodegenerative diseases |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background The panel of fluid- and imaging-based biomarkers available for neurodegenerative disease research is growing and has the potential to close important gaps in research and the clinic. With this growth and increasing use, appropriate implementation and interpretation are paramount. Various biomarkers feature nuanced differences in strengths, limitations, and biases that must be considered when investigating disease etiology and clinical utility. For example, neuropathological investigations of Alzheimer’s disease pathogenesis can fall in disagreement with conclusions reached by biomarker-based investigations. Considering the varied strengths, limitations, and biases of different research methodologies and approaches may help harmonize disciplines within the neurodegenerative disease field. Purpose of review Along with separate review articles covering fluid and imaging biomarkers in this issue of Alzheimer’s Research and Therapy, we present the result of a discussion from the 2019 Biomarkers in Neurodegenerative Diseases course at the University College London. Here, we discuss themes of biomarker use in neurodegenerative disease research, commenting on appropriate use, interpretation, and considerations for implementation across different neurodegenerative diseases. We also draw attention to areas where biomarker use can be combined with other disciplines to understand issues of pathophysiology and etiology underlying dementia. Lastly, we highlight novel modalities that have been proposed in the landscape of neurodegenerative disease research and care. | ||
| 650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurodegenerative diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Alzheimer’s disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tau |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Amyloid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neurofilament light chain |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Magnetic resonance imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Positron emission tomography |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cerebrospinal fluid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Plasma biomarkers |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Khatun, Ayesha |e verfasserin |4 aut | |
| 700 | 1 | |a Coomans, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Betts, Matthew J. |e verfasserin |4 aut | |
| 700 | 1 | |a Capraro, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Thijssen, Elisabeth H. |e verfasserin |4 aut | |
| 700 | 1 | |a Senkevich, Konstantin |e verfasserin |4 aut | |
| 700 | 1 | |a Bharucha, Tehmina |e verfasserin |4 aut | |
| 700 | 1 | |a Jafarpour, Mehrsa |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Peter N. E. |e verfasserin |4 aut | |
| 700 | 1 | |a Jagust, William |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Stephen F. |e verfasserin |4 aut | |
| 700 | 1 | |a Lashley, Tammaryn |e verfasserin |4 aut | |
| 700 | 1 | |a Grinberg, Lea T. |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Joana B. |e verfasserin |4 aut | |
| 700 | 1 | |a Mattsson-Carlgren, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Ashton, Nicholas J. |e verfasserin |4 aut | |
| 700 | 1 | |a Hanrieder, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schöll, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Ross W. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d London : BioMed Central, 2009 |g 12(2020), 1 vom: 13. Mai |w (DE-627)SPR030810736 |w (DE-600)2506521-X |x 1758-9193 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:1 |g day:13 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13195-020-00601-w |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 1 |b 13 |c 05 | ||